Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07046923 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4175408 in Participants With Advanced Cancer
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Triple Negative Breast Cancer, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT07046923: Recruiting Phase 1 study of Carcinoma, Non-Small Cell Lung and Triple Negative Breast Cancer, sponsored by Eli Lilly and Company.
NCT07046923 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Triple Negative Breast Cancer that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 240 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07046923, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Conditions Studied
Interventions
- DRUG LY4175408
Study Locations (20)
Other
- Centre Leon Berard - Lyon
- Institut Gustave Roussy - Villejuif
- Kyoto University Hospital - Kyoto
- National Cancer Center Hospital - Tokyo
- Cancer Institute Hospital of JFCR - Tokyo
Florida
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute - Orlando
- Florida Cancer Specialists - Sarasota - Sarasota
New York
- Columbia University - New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
California
- Stanford Cancer Center - Stanford
Illinois
- The University of Chicago Medical Center (UCMC) - Chicago
Indiana
- Community Health Network - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2030-07 |
| Phase | Phase 1 |
What NCT07046923 shows while recruiting
NCT07046923 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (25% lower).
The record links to 5 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which LY4175408 is the first listed.
NCT07046923 names 20 study sites across 14 states, led by Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT07046923 about?
NCT07046923 is a clinical study titled "A Study of LY4175408 in Participants With Advanced Cancer". The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could ...
What is the current status of trial NCT07046923?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2025-07-28. Estimated completion is 2030-07.
What conditions does trial NCT07046923 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Triple Negative Breast Cancer, Neoplasm Metastasis, Small Cell Lung Carcinoma, Endometrial Neoplasms.
What interventions are being tested in trial NCT07046923?
The interventions under investigation include: LY4175408 (DRUG).
Who is sponsoring clinical trial NCT07046923?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07046923 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07046923's enrollment target sits among peer trials
240 46th of 130 higher than 85 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI